Gateway Wealth Partners LLC Makes New Investment in ARK Genomic Revolution ETF $ARKG

Gateway Wealth Partners LLC acquired a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 13,222 shares of the company’s stock, valued at approximately $349,000.

A number of other large investors have also recently made changes to their positions in ARKG. Group One Trading LLC grew its holdings in shares of ARK Genomic Revolution ETF by 168.3% during the first quarter. Group One Trading LLC now owns 45,861 shares of the company’s stock valued at $1,212,000 after buying an additional 28,765 shares during the last quarter. Himension Capital Singapore PTE. LTD. acquired a new stake in shares of ARK Genomic Revolution ETF in the 1st quarter worth about $2,250,000. PNC Financial Services Group Inc. raised its holdings in shares of ARK Genomic Revolution ETF by 53.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after acquiring an additional 378 shares during the last quarter. Hanover Advisors Inc. lifted its position in ARK Genomic Revolution ETF by 20.7% in the 1st quarter. Hanover Advisors Inc. now owns 42,965 shares of the company’s stock valued at $1,135,000 after acquiring an additional 7,376 shares in the last quarter. Finally, Wealthfront Advisers LLC lifted its position in ARK Genomic Revolution ETF by 4.9% in the 1st quarter. Wealthfront Advisers LLC now owns 54,391 shares of the company’s stock valued at $1,437,000 after acquiring an additional 2,544 shares in the last quarter.

ARK Genomic Revolution ETF Trading Down 1.8%

ARKG stock opened at $38.56 on Friday. ARK Genomic Revolution ETF has a 52-week low of $22.73 and a 52-week high of $44.47. The business has a 50-day simple moving average of $37.71 and a two-hundred day simple moving average of $32.16.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.